Chem. J. Chinese Universities ›› 2025, Vol. 46 ›› Issue (1): 20240257.doi: 10.7503/cjcu20240257

• Article • Previous Articles     Next Articles

Azithromycin-loaded Polydopamine Nanoparticles for the Treatment of Periodontitis

WANG Lu1, YE Qiang1, WANG Xiuli1, ZHAO Mingcan1, LI Yi1(), HOU Yuchuan2()   

  1. 1.Department of Pediatric Dentistry,Hospital of Stomatology,Jilin University,Changchun 130021
    2.Department of Urinary,the First Hospital of Jilin University,Changchun 130021,China
  • Received:2024-05-27 Online:2025-01-10 Published:2024-06-19
  • Contact: LI Yi E-mail:lyi99@jlu.edu.cn;houyc@jlu.edu.cn
  • Supported by:
    the Medical and Healthcare Talent Construction Project of the Finance Department of Jilin Province, China(JCSZ2021893-30);the China Postdoctoral Science Foundation(2023M741344)

Abstract:

By the coordination between dimethylimidazole and ZnNO3·6H2O, the dodecahedral ZIF-8 were prepared first. Using ZIF-8 as template and dopamine hydrochloride as raw material, polydopamine nanoparticles(PDA NPs) with hollow structure were then prepared by chelation competition induced polymerization(CCIP) method. Furthermore, by using PDA NPs as drug carrier, azithromycin loaded PDA NPs(AZM@PDA NPs) were finally prepared. The hollow structure of PDA NPs contributed to high azithromycin loading with a drug loading rate of up to 20.2%. AZM@PDA NPs have high biocompatibility and low cytotoxicity, and can promote the expression of anti- inflammatory cytokines in cells. The sustained release of azithromycin achieved by AZM@PDA NPs can effectively treat periodontitis and resist alveolar ridge resorption, with good biosafety in vivo and broad application prospects.

Key words: Azithromycin, Polydopamine, Drug loading, Sustained drug release, Treatment of periodontitis

CLC Number: 

TrendMD: